While mutational analysis for EGFR, ALK, and ROS1 are standard for unresectable NSCLC [10,11], NGS analysis has not become routine and is not reimbursed by the National Health Insurance Program in Taiwan. The gene discussed is ALK; the disease is non-small cell lung carcinoma.